The exact cause of this pain remains unclear, possibly linked to the physiological changes induced by the medication
However, there are also studies which have shown little, or no effect of statin use in ovarian cancer patients [84]
We need to be able to identify patient populations that can be solely managed with a GLP-1 and populations that need a liver-targeted therapy in addition to weight loss therapy
Some FEHB plans require patients to use Teladoc or similar third-party platforms as a condition of accessing GLP-1 coverage, despite well-documented concerns about past data privacy and security incidents
Diabetologia 57(4):781784 Bray JJH, Foster-Davies H, Salem A, Hoole AL, Obaid DR, Halcox JPJ et al (2021) Glucagon-like peptide-1 receptor agonists improve biomarkers of inflammation and oxidative stress: a systematic review and meta-analysis of randomised controlled trials